Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 10.02%, which has investors questioning if this is right time to sell.

Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Armata Pharmaceuticals in a report released on Friday, March 21st. HC Wainwright analyst J. Pantginis anticipates ...

To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV). "This is a great example of a ...

A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...

Fourth Quarter 2024 and Recent Developments: The Phase 2 Tailwind study represents the second successful clinical trial for AP-PA02, Armata's lead pulmonary candidate, which was first evaluated in ...

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) is expected to post its quarterly earnings results before the ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...

Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

A research team led by Prof. ZENG Zhutian from the University of Science and Technology of China (USTC) identified and named a novel population of bladder-resident macrophages, termed suburothelial ...

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

Proceeds to be used to continue to advance development of Armata's phage product candidatesLOS ANGELES, March 12, 2025 /PRNewswire/ -- Ar ...